MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
1.520
+0.040
+2.70%
Pre Market: 1.470 -0.05 -3.29% 08:00 07/08 EDT
OPEN
1.470
PREV CLOSE
1.480
HIGH
1.530
LOW
1.440
VOLUME
9
TURNOVER
0
52 WEEK HIGH
7.66
52 WEEK LOW
1.085
MARKET CAP
107.93M
P/E (TTM)
-1.0319
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CCCC last week (0630-0704)?
Weekly Report · 1d ago
Weekly Report: what happened at CCCC last week (0623-0627)?
Weekly Report · 06/30 09:02
Weekly Report: what happened at CCCC last week (0616-0620)?
Weekly Report · 06/23 09:02
We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully
Simply Wall St · 06/20 10:29
C4 Therapeutics Holds Annual Stockholders Meeting
TipRanks · 06/18 21:23
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
Seeking Alpha · 06/16 17:50
Weekly Report: what happened at CCCC last week (0609-0613)?
Weekly Report · 06/16 09:02
Weekly Report: what happened at CCCC last week (0602-0606)?
Weekly Report · 06/09 09:02
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.